SG11202103189VA - Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents - Google Patents
Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agentsInfo
- Publication number
- SG11202103189VA SG11202103189VA SG11202103189VA SG11202103189VA SG11202103189VA SG 11202103189V A SG11202103189V A SG 11202103189VA SG 11202103189V A SG11202103189V A SG 11202103189VA SG 11202103189V A SG11202103189V A SG 11202103189VA SG 11202103189V A SG11202103189V A SG 11202103189VA
- Authority
- SG
- Singapore
- Prior art keywords
- combination
- conjugate
- agents
- diphtheria toxin
- human interleukin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/202—IL-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862753145P | 2018-10-31 | 2018-10-31 | |
| US201962832558P | 2019-04-11 | 2019-04-11 | |
| PCT/US2019/058769 WO2020092505A1 (en) | 2018-10-31 | 2019-10-30 | Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103189VA true SG11202103189VA (en) | 2021-04-29 |
Family
ID=68696513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103189VA SG11202103189VA (en) | 2018-10-31 | 2019-10-30 | Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220001020A1 (ja) |
| EP (1) | EP3873476A1 (ja) |
| JP (1) | JP2022513403A (ja) |
| KR (1) | KR20210133947A (ja) |
| CN (1) | CN113329752A (ja) |
| AU (1) | AU2019370284A1 (ja) |
| BR (2) | BR122023024088A2 (ja) |
| CA (1) | CA3117678A1 (ja) |
| IL (1) | IL282679A (ja) |
| MX (1) | MX2021004895A (ja) |
| SG (1) | SG11202103189VA (ja) |
| WO (1) | WO2020092505A1 (ja) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116685309A (zh) * | 2020-12-10 | 2023-09-01 | 斯坦林治疗公司 | 改善的冻干制剂 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007293047B2 (en) * | 2006-09-07 | 2014-01-09 | Scott & White Healthcare | Methods and compositions based on diphtheria toxin-interleukin-3 conjugates |
-
2019
- 2019-10-30 BR BR122023024088-0A patent/BR122023024088A2/pt unknown
- 2019-10-30 CA CA3117678A patent/CA3117678A1/en active Pending
- 2019-10-30 US US17/289,898 patent/US20220001020A1/en active Pending
- 2019-10-30 KR KR1020217016318A patent/KR20210133947A/ko unknown
- 2019-10-30 EP EP19809668.7A patent/EP3873476A1/en active Pending
- 2019-10-30 BR BR112021007945-9A patent/BR112021007945A2/pt unknown
- 2019-10-30 WO PCT/US2019/058769 patent/WO2020092505A1/en active Application Filing
- 2019-10-30 CN CN201980071179.0A patent/CN113329752A/zh active Pending
- 2019-10-30 JP JP2021548544A patent/JP2022513403A/ja active Pending
- 2019-10-30 SG SG11202103189VA patent/SG11202103189VA/en unknown
- 2019-10-30 AU AU2019370284A patent/AU2019370284A1/en active Pending
- 2019-10-30 MX MX2021004895A patent/MX2021004895A/es unknown
-
2021
- 2021-04-27 IL IL282679A patent/IL282679A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020092505A1 (en) | 2020-05-07 |
| IL282679A (en) | 2021-06-30 |
| MX2021004895A (es) | 2021-08-19 |
| BR122023024088A2 (pt) | 2024-02-20 |
| US20220001020A1 (en) | 2022-01-06 |
| BR112021007945A2 (pt) | 2021-08-03 |
| CN113329752A (zh) | 2021-08-31 |
| AU2019370284A1 (en) | 2021-04-22 |
| CA3117678A1 (en) | 2020-05-07 |
| KR20210133947A (ko) | 2021-11-08 |
| EP3873476A1 (en) | 2021-09-08 |
| JP2022513403A (ja) | 2022-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283838A (en) | A method of treating cancer by combined treatment | |
| IL280527A (en) | Muscle-directed couplings and their use in the treatment of dystrophinopathy | |
| HK1257249A1 (zh) | 使用脂質體伊立替康和parp抑制劑用於癌症治療的組合療法 | |
| NZ748314A (en) | Anti-cmet antibody drug conjugates and methods for their use | |
| CL2015002691A1 (es) | Miostatina antagonista en sujetos humanos | |
| SG11202011261PA (en) | Urolithin a and derivatives thereof for use in therapy | |
| IL278938A (en) | Modified atom groups that sacrifice themselves for use in prodrugs and conjugates and methods of use and preparation | |
| ZA202101824B (en) | Combination therapy using anti-ssea-4 antibody in combination with therapeutic oncology agents | |
| IL282679A (en) | A treatment method for myeloproliferative disease that includes combined therapy of interleukin 3 conjugate and diphtheria toxin in combination with other substances | |
| ZA201805403B (en) | Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor | |
| IL284053A (en) | New compounds and their use in therapy | |
| MX2023001425A (es) | Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer. | |
| IL304245A (en) | Phospholipid-flaveglin conjugates and methods of using them for targeted cancer treatment | |
| IL279653A (en) | An antibody that induces immune resistance, an induced lymphocyte, and a method of treatment of a cell therapy agent using an induced lymphocyte | |
| IL256451A (en) | Combined treatment with anti-her2 antibody coupling - drug and bcl-2 inhibitor | |
| GB2590793B (en) | Cannabidiol-C1 for use as a medicament and in the treatment of epilepsy | |
| IL277905A (en) | The history of hexadecahydro-1H-cyclopenta[A]phenanthrene for the treatment of pain and inflammation | |
| SG11202107104QA (en) | Acupoint stimulation device and acupoint stimulation method using the same | |
| IL280555A (en) | Converted benzamides and their use in therapy | |
| IL275913A (en) | Methods and combined treatment for cancer treatment | |
| RS64795B1 (sr) | Uređaj za terapijsko zračenje | |
| LT2953977T (lt) | Imunovizualizavimo agentas, skirtas naudoti su antikūno-vaisto konjugato terapija | |
| EP3787661C0 (en) | COMBINATION OF TEMOZOLOMIDE AND PAR-1 CONJUGATE FOR THE TREATMENT OF GLIOBLASTOMA | |
| IL309878A (en) | Therapeutic compounds and methods | |
| LT2953975T (lt) | Imunovizualizuojantis agentas, skirtas naudoti terapijai su antikūno-vaisto konjugatu |